Risk of esophageal and gastric cancer in patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs): A national analysis
[DOI] [PMC free article] [PubMed] [Google Scholar] 3.Severino P., DAmato A., Netti L., Pucci M., Infusino F., Maestrini V., Mancone M., Fedele F
Current clinical guidelines from organizations like the American Gastroenterological Association (2022), the Endocrine Society, and the American Association of Clinical Endocrinology support long-term pharmacotherapy for obesity management
Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Importantly, these medications are not recommended for patients with severe gastrointestinal disease, including gastroparesis, due to their effects on gastric emptying
some are specifically built for parcel or package delivery